hydrazine has been researched along with Hemorrhagic Thrombocythemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carillo, S; Cassinat, B; Chachoua, I; Constantinescu, SN; Defour, JP; Leroy, E; Levy, G; Papoular, B; Smith, SO; Varghese, LN; Zini, JM | 1 |
| Hitchcock, IS | 1 |
| Ehrlich, LA; Farrell, AT; Ko, CW; Kwitkowski, VE; Nie, L; Pazdur, R; Reaman, G | 1 |
| Boyers, D; Crowther, M; Fraser, C; Jenkinson, D; Jia, X; Mowatt, G | 1 |
1 review(s) available for hydrazine and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
Topics: Benzoates; Chronic Disease; Cost-Benefit Analysis; Humans; Hydrazines; Meta-Analysis as Topic; Models, Economic; Platelet Count; Pyrazoles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombocythemia, Essential; Thrombopoietin | 2011 |
3 other study(ies) available for hydrazine and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491.
Topics: Alleles; Amino Acid Substitution; Benzoates; Cell Line; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hydrazines; Mutation; Phenotype; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; Thrombocythemia, Essential | 2020 |
Novel ET mutations: stuck in the MPL with you.
Topics: Benzoates; Humans; Hydrazines; Mutation; Pyrazoles; Receptors, Thrombopoietin; Thrombocythemia, Essential | 2020 |
U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Drug Approval; Female; Humans; Hydrazines; Infant; Male; Pyrazoles; Thrombocythemia, Essential; United States; United States Food and Drug Administration | 2017 |